
AstraZeneca and Samsung Biologics partner up in $330m manufacturing and supply deal
pharmafile | September 22, 2020 | News story | Manufacturing and Production | AstraZeneca, Samsung BioLogics, manufacturing, pharma
AstraZeneca has announced a new global manufacturing and supply partnership with Samsung Biologics, said to be worth a potential $330.8 million.
As part of the deal, Samsung will offer its South Korea-based Plant 3 manufacturing facility to support large-scale drug substance production in support of AZ’s biologics portfolio. The plant, based in Incheon, is the largest single biomanufacturing facility in the world since opening in 2018.
For AZ, the partnership allows for an expansion of its manufacturing operations into Asia Pacific, and the company claims it will also “accelerate bio-health innovation” in South Korea.
Besides this, few details were revealed on the nature of the partnership, though it was noted that there was potential for the deal to be expanded to a value of $545.6 million in future.
Samsung Biologics CEO Dr Tae Han Kim said the company was “very proud” to be syncing up with AZ under the deal, while the latter firm’s Executive Vice President of Global Operations and IT, Pam Cheng, said the partnership “strengthens our manufacturing capabilities, and ensures we are well-positioned to continue to deliver our exciting portfolio of new and established biologics medicines to patients with quality, speed and efficiency.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …






